Project Grant R01DK142858
Award Date 8/18/25
Completion Date 6/30/30
Dollars Obligated $786K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
- This Project Grant award of $153,554 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to unveil novel targets for type 1 diabetes (T1D) therapy. The principal investigator at the Beckman Research Institute of the City of Hope will utilize innovative methodologies, including human pancreatic tissue slices, to investigate the functional heterogeneity...
- This $816,325 Cooperative Agreement, awarded on August 1, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to optimize novel "PAIR" pharmacological agents targeting the unfolded protein response (UPR) for the treatment of type 1 diabetes (T1D). The primary objectives are to: 1) further develop and characterize the potency and selectivity of...
- This federal Project Grant award of $2,263,983, awarded on September 5, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to engineer regulatory T cells (Tregs) for the treatment of type 1 diabetes (T1D). The key products or services to be delivered through this funding include: Developing "designer" antigen-specific Tregs using chimeric...
- This federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The $621,794 award to Islex Therapeutics, LLC will support the preclinical development of a novel, islet-targeted antibody therapy for the treatment of Type 1 Diabetes (T1D). The objective is to establish proof-of-principle for a humanized version of an antibody that has...
- The University of Florida received a $132,270 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) on December 26, 2024. The grant will support the development of a multi-functional, 3D-printed biomaterial scaffold to improve the vascularization, engraftment, and immunoprotection of transplanted pancreatic islets for the treatment of type 1 diabetes. The key objectives are to: (1) identify scaffold geometric features that result in robust...
- This federal Cooperative Agreement award, with a total funding amount of $1,207,770.00 and an award date of January 1, 2025, was granted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award will support research to investigate the role of genetically-controlled thymic epithelial cell (TEC) and hematopoietic stem cell (HSC) abnormalities in driving the development...
- This $3,140,632 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to elucidate the mechanisms underlying human endocrine lineage commitment and harness this knowledge to improve strategies for beta cell replacement in diabetes treatment. The long-term objectives are to generate in vitro-derived beta cells that recapitulate endogenous function, which could lead to...
- The U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $372,067 Project Grant to Aleutian Therapeutics, Inc. under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant is for the "Development of an Immune Evasive Stem Cell Line for Type 1 Diabetes Regenerative Therapy." The project aims to develop an immune-evasive stem cell line that could potentially be used in regenerative therapies for type 1...
- This federal Project Grant award of $455,491.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research program, supports research on the role of T follicular helper cells (Tfh) in regulating T cell-mediated type 1 diabetes (T1D). The research will be conducted by the University of North Carolina at Chapel Hill (UNC-CH) from August 1, 2025 to May 31, 2030. The key objectives are to...
- This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $199,999 to the University of Florida to develop innovative artificial intelligence (AI)-based methods to support the discovery of potent, orally available small-molecule heparanase inhibitors. The goal is to evaluate these novel heparanase inhibitors in murine models as a...